FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971296952> ?p ?o ?g. }

• W1971296952 endingPage "481" @default.
• W1971296952 startingPage "467" @default.
• W1971296952 abstract "Summary. The purpose of this study was to investigate the pharmacokinetics and dosimetry of using [111In]-labelled F(ab')2 fragments against prostate acid phosphatase (FC-3001, Orion Corporation Farmos, Finland) for the detection of metastatic prostate cancer. Five patients in all were subjected to intraprostatic injection of 1 mg FC-3001 labelled with 85–100 MBq [111In]. In four of the patients the biodistribution was studied by sequential whole-body counting, gamma-camera scintigraphy of the abdomen in anteroposterior and postero-anterior projections. Blood and urine samples were collected sequentially up to 72 h after injection. Initially, significant amounts of antibody fragments were released from the site of injection. After the first 4 h, 22.0% of injected antibody (2.2–41.3%ID) remained in the prostate and was slowly released with a final half-life of 80.4 h (49.9–141.8 h). Labelled antibody appeared in the blood shortly after injection and was cleared from the blood with a final half-life of 27.7–300.9 h. The liver, the bone marrow and, in two patients, the kidneys accumulated antibody fragments in significant amounts during the period of investigation. An apparent relationship between the initial whole-body clearance and renal uptake is described. The effective dose averaged 0.37 mSv/MBq (range 0.24-0.52 mSv/MBq). The highest equivalent doses were received by the kidneys (0.46-2.81 mGy/MBq) the liver (0.44-1.59 mGy/MBq) and the bone marrow (0.37-0.57 mGy MBq). Only in two of the patients with known metastases were pathological foci seen. The disappointing imaging results were probably caused by the biphasic release of antibody from the prostate, and indicates that intraprostatic injection of this antibody has no advantage for imaging, as well as being unpleasant for the patient. The biodistribution of the antibody following release from the prostate is similar to but more variable than the biodistribution seen in patients after intravenous injection of labelled antibodies." @default.
• W1971296952 created "2016-06-24" @default.
• W1971296952 creator A5037225529 @default.
• W1971296952 creator A5041614637 @default.
• W1971296952 creator A5065994009 @default.
• W1971296952 creator A5079575278 @default.
• W1971296952 creator A5085846917 @default.
• W1971296952 date "1995-09-01" @default.
• W1971296952 modified "2023-09-23" @default.
• W1971296952 title "Pharmacokinetics and dosimetry of [111In] F(ab‘)2 fragments against prostatic acid phosphatase after intraprostatic injection for immunoscintigraphy in prostate cancer" @default.
• W1971296952 cites W1965074073 @default.
• W1971296952 cites W1985872247 @default.
• W1971296952 cites W1998761058 @default.
• W1971296952 cites W1999312609 @default.
• W1971296952 cites W2005843541 @default.
• W1971296952 cites W2007562076 @default.
• W1971296952 cites W2011484282 @default.
• W1971296952 cites W2015329310 @default.
• W1971296952 cites W2026139125 @default.
• W1971296952 cites W2044538257 @default.
• W1971296952 cites W2051084337 @default.
• W1971296952 cites W2068410581 @default.
• W1971296952 cites W2088018909 @default.
• W1971296952 cites W2415881751 @default.
• W1971296952 cites W2475230807 @default.
• W1971296952 cites W279593907 @default.
• W1971296952 doi "https://doi.org/10.1111/j.1475-097x.1995.tb00536.x" @default.
• W1971296952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8846667" @default.
• W1971296952 hasPublicationYear "1995" @default.
• W1971296952 type Work @default.
• W1971296952 sameAs 1971296952 @default.
• W1971296952 citedByCount "1" @default.
• W1971296952 crossrefType "journal-article" @default.
• W1971296952 hasAuthorship W1971296952A5037225529 @default.
• W1971296952 hasAuthorship W1971296952A5041614637 @default.
• W1971296952 hasAuthorship W1971296952A5065994009 @default.
• W1971296952 hasAuthorship W1971296952A5079575278 @default.
• W1971296952 hasAuthorship W1971296952A5085846917 @default.
• W1971296952 hasConcept C112705442 @default.
• W1971296952 hasConcept C121608353 @default.
• W1971296952 hasConcept C126322002 @default.
• W1971296952 hasConcept C126894567 @default.
• W1971296952 hasConcept C142724271 @default.
• W1971296952 hasConcept C159654299 @default.
• W1971296952 hasConcept C185592680 @default.
• W1971296952 hasConcept C202751555 @default.
• W1971296952 hasConcept C203014093 @default.
• W1971296952 hasConcept C2776146153 @default.
• W1971296952 hasConcept C2776235491 @default.
• W1971296952 hasConcept C2776490512 @default.
• W1971296952 hasConcept C2777064799 @default.
• W1971296952 hasConcept C2777807558 @default.
• W1971296952 hasConcept C2779902710 @default.
• W1971296952 hasConcept C2780007613 @default.
• W1971296952 hasConcept C2780026642 @default.
• W1971296952 hasConcept C2780192828 @default.
• W1971296952 hasConcept C2989005 @default.
• W1971296952 hasConcept C542903549 @default.
• W1971296952 hasConcept C55493867 @default.
• W1971296952 hasConcept C71924100 @default.
• W1971296952 hasConcept C75088862 @default.
• W1971296952 hasConceptScore W1971296952C112705442 @default.
• W1971296952 hasConceptScore W1971296952C121608353 @default.
• W1971296952 hasConceptScore W1971296952C126322002 @default.
• W1971296952 hasConceptScore W1971296952C126894567 @default.
• W1971296952 hasConceptScore W1971296952C142724271 @default.
• W1971296952 hasConceptScore W1971296952C159654299 @default.
• W1971296952 hasConceptScore W1971296952C185592680 @default.
• W1971296952 hasConceptScore W1971296952C202751555 @default.
• W1971296952 hasConceptScore W1971296952C203014093 @default.
• W1971296952 hasConceptScore W1971296952C2776146153 @default.
• W1971296952 hasConceptScore W1971296952C2776235491 @default.
• W1971296952 hasConceptScore W1971296952C2776490512 @default.
• W1971296952 hasConceptScore W1971296952C2777064799 @default.
• W1971296952 hasConceptScore W1971296952C2777807558 @default.
• W1971296952 hasConceptScore W1971296952C2779902710 @default.
• W1971296952 hasConceptScore W1971296952C2780007613 @default.
• W1971296952 hasConceptScore W1971296952C2780026642 @default.
• W1971296952 hasConceptScore W1971296952C2780192828 @default.
• W1971296952 hasConceptScore W1971296952C2989005 @default.
• W1971296952 hasConceptScore W1971296952C542903549 @default.
• W1971296952 hasConceptScore W1971296952C55493867 @default.
• W1971296952 hasConceptScore W1971296952C71924100 @default.
• W1971296952 hasConceptScore W1971296952C75088862 @default.
• W1971296952 hasIssue "5" @default.
• W1971296952 hasLocation W19712969521 @default.
• W1971296952 hasLocation W19712969522 @default.
• W1971296952 hasOpenAccess W1971296952 @default.
• W1971296952 hasPrimaryLocation W19712969521 @default.
• W1971296952 hasRelatedWork W114245097 @default.
• W1971296952 hasRelatedWork W1803114945 @default.
• W1971296952 hasRelatedWork W1997716688 @default.
• W1971296952 hasRelatedWork W2002051579 @default.
• W1971296952 hasRelatedWork W2056601883 @default.
• W1971296952 hasRelatedWork W2122716219 @default.
• W1971296952 hasRelatedWork W2127016727 @default.
• W1971296952 hasRelatedWork W2160751658 @default.
• W1971296952 hasRelatedWork W2552311726 @default.

• next